Hemostemix Inc. (CVE:HEM – Get Free Report) shot up 33.3% on Wednesday . The stock traded as high as C$0.14 and last traded at C$0.14. Approximately 485,625 shares traded hands during mid-day trading, an increase of 33% from the average session volume of 366,110 shares. The stock had previously closed at C$0.11.
Hemostemix Price Performance
The firm has a market cap of C$20.91 million, a price-to-earnings ratio of -12.00 and a beta of 0.20. The business has a 50-day moving average of C$0.09 and a 200-day moving average of C$0.07.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Further Reading
- Five stocks we like better than Hemostemix
- What Does a Stock Split Mean?
- Driving Forward: Lucid’s Growing Sales and Gravity SUV’s Impact
- What Makes a Stock a Good Dividend Stock?
- Why Amazon’s Next Earnings Could Trigger a Stock Breakout
- Conference Calls and Individual Investors
- With This Kind of Data, The Fed Isn’t Cutting Rates This Year
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
